An open-label phase II trial to evaluate the efficacy and safety of gefitinib in patients with locally advanced, relapsed or metastatic renal cell cancer. - Jermann,M.; Joerger,M.; Pless,M.; Salzberg,M.; Gillessen,S.; Morant,R.; Egli,F.; Rhyner,K.; Bauer,J.A.; Stahel,R.A. (Proc Am Soc Clin Oncol, 2003)